Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Viemed Healthcare ( (VMD) ).
Viemed Healthcare reported record net revenues of $71.9 million for the third quarter of 2025, marking a 24% increase from the previous year. The company’s strategic acquisition of Lehan’s Medical Equipment and completion of its share repurchase program have contributed to its financial growth, enhancing market presence and diversifying service capabilities. The company also updated its full-year 2025 financial guidance, reflecting increased visibility into the year’s remainder, with expectations for net revenue and adjusted EBITDA slightly adjusted. These developments underscore Viemed’s commitment to shareholder value and patient outcomes.
The most recent analyst rating on (VMD) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.
Spark’s Take on VMD Stock
According to Spark, TipRanks’ AI Analyst, VMD is a Outperform.
Viemed Healthcare’s overall stock score is driven by strong earnings call performance and solid financial stability. The company’s strategic growth initiatives and raised guidance are significant positives. However, liquidity concerns due to negative free cash flow and moderate valuation metrics slightly temper the outlook.
To see Spark’s full report on VMD stock, click here.
More about Viemed Healthcare
Viemed Healthcare, Inc. is a provider of in-home clinical care, specializing in post-acute respiratory healthcare equipment and services in the United States.
Average Trading Volume: 216,265
Technical Sentiment Signal: Sell
Current Market Cap: $253.7M
Find detailed analytics on VMD stock on TipRanks’ Stock Analysis page.